Number of Employees: Approximately 3,000
Marlboro, L&M, Shelton, Dallas, Muratti, Luxor, Sampoerna, Chanceller
Welcome to Philip Morris Brazil. We are the second largest tobacco company in the country and we are proud to have been able to offer quality products to Brazilian adult smokers for almost 40 years.
Our portfolio includes brands such as Marlboro, Shelton, Dallas, and Muratti, which are made in our factory in Santa Cruz do Sul (RS). Approximately 2,700 dedicated and talented people work for Philip Morris Brazil across our locations, including over 1,600 employees in our factory. In addition, we are one of the major tobacco leaf buyers in Brazil.
We take our role in the local communities in which we operate very seriously and actively support initiatives to promote education and prevent child labor in tobacco growing.
Philip Morris signs a Consent Decree with CADE.
Read here the public statement that was issued.
To access the Consent Decree signed on January 23rd 2013, click here.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in enclosed public places.
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, total bans on communications to adult consumers, and bans on the use of ingredients in tobacco products.